Equity Derivatives and Volatility Specialist, Clifton Derivatives

John Ley

Equity Derivatives and Volatility Specialist

Clifton Derivatives

Independent derivative and volatility research firm focusing on events/catalysts, earnings, relative value and cross asset volatility strategies.

Equity Derivatives

<ul>
<li>Weak index performance and range break coincided with rising volatility and weak breadth across single stocks.</li>
<li>Option activity picked up sharply, with flows suggesting a more defensive tone emerging during the week.</li>
<li>A variety of metrics point towards a sharp increase in hedging.</li>
</ul>


Weak index performance and range break coincided with rising volatility and weak breadth across single stocks.
Option activity picked up sharply, with flows suggesting a more defensive tone emerging during the week.
A variety of metrics point towards a sharp increase in hedging.


Hong Kong Single Stock Options Weekly (Mar 23–27): Volatility Rises Amid Increased Hedging Activity

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/wuxi-apptec-co-ltd-bf4a1265-beef-48b6-b82d-29308426030f" target="_blank" data-smartkarma-citation="entities:27795:1" rel="noopener">WuXi AppTec (2359 HK)</a> has announced 2025 result, with both revenue and net profit reaching record highs. Revenue increased 16% YoY to RMB45.5B, ahead of guidance of RMB43.5–44.0B.</li>
<li>With continuous capacity expansion to better meet customer demand, backlog for continuing operations reached a record high of RMB58B by the end of 2025, up 29% YoY.</li>
<li>Based on the current order backlog, Wuxi AppTec expects total revenue to reach RMB51.3–53.0B in 2026, with continuing operations revenue growing 18%–22% YoY.</li>
</ul>



WuXi AppTec (2359 HK) has announced 2025 result, with both revenue and net profit reaching record highs. Revenue increased 16% YoY to RMB45.5B, ahead of guidance of RMB43.5–44.0B.
With continuous capacity expansion to better meet customer demand, backlog for continuing operations reached a record high of RMB58B by the end of 2025, up 29% YoY.
Based on the current order backlog, Wuxi AppTec expects total revenue to reach RMB51.3–53.0B in 2026, with continuing operations revenue growing 18%–22% YoY.


WuXi AppTec (2359 HK): Core Business Drives 2025 Performance; Momentum to Continue

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyse the changes of A-H premium on 179 stocks over the last week. The average A-H premium was 69.0% as of Mar 20th.</li>
<li>The average A-H premium changed by -1.2ppt week-on-week, led by industrials, financials, energy and offset by materials, real estate.</li>
<li>We highlight weekly changes in A-H premium for CATL, China Longyuan Power, Yankuang Energy, Shenzhen Woer Heat, CIMC, Anhui Conch Cement.</li>
</ul>


We analyse the changes of A-H premium on 179 stocks over the last week. The average A-H premium was 69.0% as of Mar 20th.
The average A-H premium changed by -1.2ppt week-on-week, led by industrials, financials, energy and offset by materials, real estate.
We highlight weekly changes in A-H premium for CATL, China Longyuan Power, Yankuang Energy, Shenzhen Woer Heat, CIMC, Anhui Conch Cement.


A-H Premium Weekly (Mar 20th): CATL, China Longyuan Power, Yankuang Energy, Shenzhen Woer Heat, CIMC

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Mar 13th.</li>
<li>Top short increases and decreases were tabulated for one week and four week period.</li>
<li>We highlight short changes in Tencent, Alibaba, CNOOC, Petrochina, Cmoc, Yankuang Energy, Sinopec, CSPC Pharma.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Mar 13th.
Top short increases and decreases were tabulated for one week and four week period.
We highlight short changes in Tencent, Alibaba, CNOOC, Petrochina, Cmoc, Yankuang Energy, Sinopec, CSPC Pharma.


HK Short Interest Weekly: Tencent, Alibaba, CNOOC, Petrochina, Cmoc, Yankuang Energy, Sinopec

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Genfleet Therapeutics / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/genfleet-therapeutics" target="_blank" data-smartkarma-citation="entities:44187:1" rel="noopener">GenFleet Therapeutics</a> (GFT) raised around US$240m in its Hong Kong IPO in September 2025. The lockup on its cornerstone investors is set to expire soon.</li>
<li>GFT is a biopharmaceutical company focused on developing novel treatment options in the fields of oncology.</li>
<li>In this note, we will talk about the lockup dynamics and possible placement.</li>
</ul>



GenFleet Therapeutics (GFT) raised around US$240m in its Hong Kong IPO in September 2025. The lockup on its cornerstone investors is set to expire soon.
GFT is a biopharmaceutical company focused on developing novel treatment options in the fields of oncology.
In this note, we will talk about the lockup dynamics and possible placement.


GenFleet Therapeutics IPO Lockup - A Minor Prelude to a Much Bigger Release

China

WuXi AppTec Co., Ltd. manufactures medical products. The Company produces biological agents, antibodies, biological diagnostic reagents, and other products. WuXi AppTec also provides biological analysis, technical study, and other services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

WuXi AppTec (603259 CH)

Hong Kong Single Stock Options Weekly (Mar 23–27): Volatility Rises Amid Increased Hedging Activity

Rising volatility and weaker breadth set the tone for the week, with option flows and ETF activity pointing to a clear shift toward increased hedging.

John Ley

WuXi AppTec (2359 HK): Core Business Drives 2025 Performance; Momentum to Continue

WuXi AppTec reports record-high revenue and net profit in 2025, with backlog reaching RMB58B. The company guided for 2026 revenue of...

Tina Banerjee

A-H Premium Weekly (Mar 20th): CATL, China Longyuan Power, Yankuang Energy, Shenzhen Woer Heat, CIMC

We analyzed A-H premium changes in the past week and highlight A-H premium changes for CATL, China Longyuan Power, Yankuang Energy, Shenzhen Woer...

Ke Yan, CFA, FRM

HK Short Interest Weekly: Tencent, Alibaba, CNOOC, Petrochina, Cmoc, Yankuang Energy, Sinopec

We analyzed the latest HK SFC report for aggregate short position as of Mar 13th and highlight short interest changes in Tencent, Alibaba, CNOOC,...

Ke Yan, CFA, FRM

GenFleet Therapeutics IPO Lockup - A Minor Prelude to a Much Bigger Release

GenFleet Therapeutics (GFT) raised around US$240m in its Hong Kong IPO in September 2025. The lockup on its cornerstone investors is set to expire...

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Hong Kong Single Stock Options Weekly (Mar 23–27): Volatility Rises Amid Increased Hedging Activity

Rising volatility and weaker breadth set the tone for the week, with option flows and ETF activity pointing to a clear shift toward increased hedging.

John Ley

WuXi AppTec (2359 HK): Core Business Drives 2025 Performance; Momentum to Continue

​WuXi AppTec reports record-high revenue and net profit in 2025, with backlog reaching RMB58B. The company guided for 2026 revenue of...

Tina Banerjee

A-H Premium Weekly (Mar 20th): CATL, China Longyuan Power, Yankuang Energy, Shenzhen Woer Heat, CIMC

We analyzed A-H premium changes in the past week and highlight A-H premium changes for CATL, China Longyuan Power, Yankuang Energy, Shenzhen Woer...

Ke Yan, CFA, FRM

HK Short Interest Weekly: Tencent, Alibaba, CNOOC, Petrochina, Cmoc, Yankuang Energy, Sinopec

We analyzed the latest HK SFC report for aggregate short position as of Mar 13th and highlight short interest changes in Tencent, Alibaba, CNOOC,...

Ke Yan, CFA, FRM

GenFleet Therapeutics IPO Lockup - A Minor Prelude to a Much Bigger Release

GenFleet Therapeutics (GFT) raised around US$240m in its Hong Kong IPO in September 2025. The lockup on its cornerstone investors is set to expire...

Sumeet Singh

WuXi AppTec reports record-high revenue and net profit in 2025, with backlog reaching RMB58B. The company guided for 2026 revenue of...